Latest Headlines

Latest Headlines

Singapore's ASLAN marks a first for ASLAN001 with Hyundai Pharm

Singapore-based ASLAN Pharmaceuticals has notched a first in its efforts to develop immunotherapies and targeted agents for Asia-prevalent tumor types under a refined cost model, roping in South Korea's Hyundai Pharmaceutical in a development and license deal of ASLAN001 for the treatment of a form of bile duct cancer, cholangiocarcinoma.

South Korea's Hanmi signs $4.2B diabetes deal

South Korea-based Hanmi Pharmaceutical has signed a deal with French pharma giant Sanofi to license its GLP-1 diabetes treatments as Sanofi attempts to revive its diabetes division, according to a report by Reuters.

Sanofi bets another $1.7B on diabetes to pad its lagging pipeline

Sanofi, stockpiling diabetes assets with eyes on Novo Nordisk and Eli Lilly, inked a deal worth up to $1.7 billion to bring in a late-stage treatment for the disease, partnering up with Lexicon Pharmaceuticals.

Sanofi inks a $4.2B diabetes deal, playing pipeline catch-up with Novo and Lilly

Sanofi signed a deal worth up to $4.2 billion to get its hands on a trio of diabetes treatments from South Korean drugmaker Hanmi Pharmaceutical, filling out its pipeline as it contends with rivals Novo Nordisk and Eli Lilly.

Accelovance strikes a nonprofit partnership to reach developing world

CRO Accelovance is pairing up with a nonprofit clinical research outfit to bring its services to the developing world.

Eisai pairs up with a French research shop to find new cancer drugs

Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.

Allergan bets $50M on a dry eye drug as it touts its commitment to R&D

Allergan expanded its pipeline with a $50 million deal to bring in a late-stage treatment for dry eye as the company works to reaffirm its commitment to R&D in the face of industrywide scrutiny.

Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners

Sanofi is pairing up with Germany's BioNTech in a collaboration potentially worth $1.5 billion, licensing some early-stage cancer immunotherapies that use messenger RNA to target tumors.

China's WuXi PharmaTech, Gilead focus on analytical testing in wider partnership

Shanghai-based WuXi PharmaTech has opened a door for Gilead Sciences in China that comes as the California-based maker of blockbuster hepatitis C drugs Sovaldi and Harvoni looks to expand in Asia, and particularly in China, for its leading therapies.

MabSpace gets $15M as Lilly Asian Ventures bets on immune approach

Suzhou-based MabSpace Biosciences has raised $15 million in Series A funding from Lilly Asia Ventures to develop the biotech's technology for antibodies that break the tolerance of the immune system.